Ouabain mimics low temperature rescue of F508del-CFTR in cystic fibrosis epithelial cells

Donglei Zhang1,†, Fabiana Ciciriello1,†, Suzana M. Anjos1, Annamaria Carissimo2, Jie Liao3, Graeme W. Carlile1, Haouaria Balghi1, Renaud Robert4, Alberto Luini2,4, John W. Hanrahan4 and David Y. Thomas1

1 Department of Biochemistry, McGill University, Montréal, QC, Canada
2 Telethon Institute of Genetics and Medicine, Naples, Italy
3 Department of Physiology, McGill University, Montréal, QC, Canada
4 Institute of Protein Biochemistry, National Research Council, Naples, Italy

*Correspondence: Donglei Zhang, Department of Biochemistry, McGill University, 3655 Promenade Sir William Osler, Montréal, QC, Canada H3G 1Y6. e-mail: donglei.zhang@mcgill.ca; Fabiana Ciciriello, Telethon Institute of Genetics and Medicine, Via Pietro Castellino 111, 80131 Naples, Italy. e-mail: fabulous.cici@gmail.com
†Donglei Zhang and Fabiana Ciciriello have contributed equally to this work.

INTRODUCTION

Cystic fibrosis (CF) is caused by mutations in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR), which functions as a plasma membrane anion channel (Riordan et al., 1989; Anderson et al., 1991; Karrner et al., 1991). The most common CFTR mutation, F508del (Rommens et al., 1989), causes retention of the mutant in the ER and its premature degradation by the proteasome (Cheng et al., 1990; Jensen et al., 1995). Nevertheless, F508del-CFTR can form functional channels having reduced activity (Dalemans et al., 1991), moreover its trafficking is temperature sensitive and can be partially rescued in many cell types by incubation at low temperature (≤29˚C; Denning et al., 1992; Rennolds et al., 2008). It has been estimated that restoring 10–25% of wild-type CFTR (WT-CFTR) activity in patients would alleviate the major symptoms of CF (Pilewski and Frizzell, 1999; Zhang et al., 2009).

Cell-based assays for “correctors” of F508del-CFTR trafficking have identified chemically diverse small molecules that correct trafficking with variable efficiency (Pedemonte et al., 2005; Van Goor et al., 2006; Carlile et al., 2007). Some of these correctors are thought to interact directly with CFTR by acting as stabilizing ligands or “pharmacological chaperones” (Loo et al., 2006; Sampson et al., 2011) or on other known cellular targets, e.g., phosphodiesterases (Dormer et al., 2005; Robert et al., 2008) and histone deacetylases (Hutt et al., 2010). However, for the majority of correctors that have been described, neither the target nor the mechanism of action are known (Lukacs and Verkman, 2012). We have previously reported a novel cell-based HTS assay that measures the appearance of HA-tagged F508del-CFTR at the surface of BHK cells (Carlile et al., 2007). Using this assay in a high throughput screen we identified the cardiac glycoside ouabagenin, an aglycone of ouabain, as a moderately potent corrector of F508del-CFTR trafficking. Cardiac glycosides have long been used to treat congestive heart failure and cardiac arrhythmia, and digoxin is still prescribed for atrial fibrillation and atrial flutter (Prassas and Diamandis, 2008). Cardiac glycosides bind to a highly conserved site on human Na+/K+-ATPase alpha subunits with a Kd of ~18 nM (Wang et al., 2001), which is expected to increase several fold in the presence of physiological potassium concentrations. In cardiac myocytes inhibiting the pump increases intracellular sodium and reduces membrane sodium/calcium exchange, leading to elevation of intracellular calcium and increased contractile force (Hoyer et al., 2011). Moreover, clinical studies also suggest that cardiac
glycosides inhibit cancer cell proliferation and have potential as novel therapeutic agents against cancer (Newman et al., 2008).

In addition to its action as an inhibitor of Na+/K+-ATPase, ouabain has a signaling function at low concentrations (1–10 nM) that is independent of its effect on ion transport (Zhang et al., 2006). Ouabain-bound Na+/K+-ATPase can trigger slow calcium oscillations and NF-kB activation, thereby preventing cell death and promoting the proliferation and viability of kidney proximal tubule cells (Li et al., 2006). Interestingly, it has been reported that digoxin and other cardiac glycosides suppress IL-8-dependent lung inflammation in CF lung epithelial cells (Srivastava et al., 2004). The exact mechanisms by which cardiac glycosides modulate cell proliferation, inflammation, migration, and apoptosis are not known (Aperia, 2007; Prassas and Diamandis, 2008).

Here we describe a novel function for ouabain and its analogs which is linked to its signaling functions. Treatment with low concentrations of ouabain resulted in the functional rescue of F508del-CFTR in human CF bronchial epithelial cells, and also in BHK cells and CF mice that are expected to be less sensitive to ouabain inhibition. Moreover, the mechanisms of correction by ouabain and its analogs resemble those of low temperature according to transcriptional profiling and analysis of the Connectivity Map (CMAP) for F508del-CFTR trafficking in polarized parental CFBE410-cells. Significant connectivity was observed between ouabain and low temperature transcriptional profiles obtained in human CF bronchial epithelial cells and this relationship was confirmed by hierarchical clustering analysis of the expression patterns.

These results reveal a new function for ouabain and its analogs as regulators of F508del-CFTR protein trafficking and indicate that cardiac glycosides act by mimicking low temperature rescue. Transcriptional profiling provides insight into correction mechanisms, and small molecules that mimic the low temperature signature may be useful in developing therapeutics that correct the trafficking defect in CF.

RESULTS
CARDIAC GLYCOSIDES CORRECT THE TRAFFICKING OF F508del-CFTR TO THE CELL SURFACE
From our initial observation that ouabagenin, can correct F508del-CFTR trafficking in BHK cells (Carlile et al., 2007), we selected a panel of structurally related cardiac glycosides, including ouabain, digoxin, and digitoxin (Figure 1A). To confirm that they increase the trafficking of F508del-CFTR to the plasma membrane, we treated BHK cells that express F508del-CFTR-3HA, and measured the appearance of the HA epitope (Carlile et al., 2007). F508del-CFTR-3HA was detectable at the cell surface after 2 h treatment and after 24 h surface expression was increased about 20–30% compared to time 0 h treated cells (Figure 1B).

CARDIAC GLYCOSIDES IMPROVE STABILITY AND TRAFFICKING OF F508del-CFTR
The ER-retained glycoform of F508del-CFTR (band B, ~150 kD) acquires terminal glycosylation (forming band C, ~175 kD) and traffics through the Golgi. We used immunoblotting to detect the appearance of the mature glycosylated “band C” form of F508del-CFTR in human CF bronchial epithelial cells (CFBE410-) treated with the individual cardiac glycosides and we evaluated their efficacy in promoting trafficking correction (Figure 2A). We compared the amount of band C with that found in cells treated at low temperature (29˚C). Treatment with 100 nM ouabain, digitoxin, or digoxin, or 1 μM ouabagenin, increased the steady-state expression of immature (band B) and mature (band C) glycoforms of F508del-CFTR by 2- to 15-fold above vehicle control (Figure 2B). We also observed an increase in core-glycosylated F508del-CFTR (band B) upon treatment with the cardiac glycosides (Figures 2A,B). There is an overall increase in CFTR protein in the presence of cardiac glycosides, which could result in a “leaky” ER. In order to assess whether the observed increase in trafficking (band C) resulted from ER overload, we calculated the ratio of band C/B (Hurt et al., 2010). We found that all the cardiac glycosides (ouabain, digoxin, and digoxin) increased the ratio of C/B bands by three- to seven-fold compared with vehicle control (Figure 2B) without affecting Na+/K+-ATPase protein expression (Figure 2A).

In Figure 2C, we compared our own anti-CFTR antibody (23C5) which we have utilized throughout this whole study to the commercial anti-CFTR antibody (M3A7, from Chemicon). The results show that both antibodies gave the similar results, and our own anti-CFTR antibody can detect CFTR bands using much less cell lysates compared with using commercial antibody. To test if these cardiac glycosides have cytotoxicity on CFBE cells or not, in Figure 3, we measured the cell proliferation after 24 h of treatment with each individual cardiac glycoside on CFBE cells, and the results showed that there is no significant cytotoxicity on CFBE cells under 100 nM concentration of cardiac glycosides. Taken together these results show a novel function for ouabain and its analogs in F508del-CFTR folding and trafficking, beyond its well-established role in ion homeostasis.

OUABAIN RESCUES F508del-CFTR FUNCTION
We next investigated if ouabain and its analogs could also rescue F508del-CFTR channel activity. When CFBE/F508del-CFTR cells were pre-treated with 100 nM ouabain, digoxin, digitoxin, or with 1 μM ouabagenin for 24 h, the iodicide efflux response evoked by forskolin increased to levels that were 26–32% that of CFBE cells expressing (WT-CFTR; Figure 4A).

These results were confirmed by measuring the short circuit current (see Materials and Methods) across polarized CFBE/F508del-CFTR cells that had been pre-treated with 100 nM ouabain for 24 h (Figures 4B1–V). A trans-epithelial chloride gradient was imposed and the basolateral membrane was permeabilized using nystatin to ensure that the Isc response was mediated by apical Cl− conductance (Robert et al., 2008). Representative Isc recordings are shown for WT-CFTR monolayers (Figure 4B1) and F508del-CFTR monolayers pre-incubated for 24 h with normal saline at low temperature (29˚C; Figure 4BII), with DMSO vehicle at 37˚C (Figure 4BIII), or with 100 nM ouabain at 37˚C (Figure 4BIV). Ouabain pre-treatment increased the forskolin and genistein-stimulated Isc by ~1.7-fold compared with controls (Figures 4BIII–V, P < 0.05). Chloride current was abolished by the CFTR inhibitor CHFRIinh-172 (Ma et al., 2002; Caci et al., 2008) in each instance, confirming that the stimulated Isc was mediated by CFTR channels. The magnitude of the CFTR-mediated current induced by ouabain (n = 7) was 7.5% of that induced by
Zhang et al. Rescue of F508del-CFTR by ouabain

FIGURE 1 | Cardiac glycosides induce trafficking of HA-tagged F508del-CFTR to the cell surface. (A) Chemical structures of cardiac glycosides tested in this study. (B) BHK cells expressing F508del-CFTR-3HA were treated with 0.1 µM ouabain, 0.1 µM digitoxin, 0.1 µM digoxin, and 1.0 µM ouabagenin for various time points or with the vehicle control (0.1% DMSO), the cell surface expression of CFTR were monitored by immunofluorescence assay. Data are presented as percentage increase in surface CFTR signal compared to controls (mean ± SD of n = 4; *P < 0.05, **P < 0.005).

low temperature (n = 6), which represents 1.4% of the current measured in cells expressing WT-CFTR (n = 9; Figure 4BV).

The correction of F508del-CFTR trafficking and function by ouabain pre-treatment was further evaluated in vivo using a CF mouse salivary secretion assay. The F508del-CFTR trafficking defect can be assayed functionally in the ileum and salivary glands of this CF mouse model (French et al., 1996; Robert et al., 2010). Homozygous F508del-CFTR mice and littermate WT controls received continuous low doses of ouabain (0.01 mg/kg/day) or vehicle for 48 h using a micro-osmotic pump implanted under the skin. Salivary secretion was measured acutely by injection of atropine and then isoprenaline into the cheek. Chronic exposure to low levels of ouabain in vivo increased the salivary secretion response by ~5-fold (Figure 4G; *P < 0.04, n = 5). This value corresponds to ~8.1% of the secretory response of littermate WT control mice.

In summary, these data provide evidence that ouabain enhances F508del-CFTR trafficking and channel activity in vitro in human CF epithelial cells (CFBE41o-) and in vivo in F508del-CFTR homozygous CF mice.

OUABAIN REDUCES THE ER CALCIUM STORES IN CFBE CELLS

Retention of misfolded proteins in the endoplasmic reticulum is regulated by chaperone proteins, many of which require [Ca²⁺] for optimal activity. Although controversial, several studies have shown that [Ca²⁺] signaling is elevated in CF and that calcium homeostasis in CF airway epithelial cells is disturbed and related to the retention of F508del-CFTR proteins in the ER (Antigny...
FIGURE 2 | Cardiac glycosides correct trafficking of F508del-CFTR in CF bronchial epithelial cells. (A) CFBE/F508del-CFTR cells were treated with individual concentrations of ouabain, ouabagenin, digoxin, or digitoxin for 48 h and the cell lysates were analyzed by western blotting using anti-CFTR, anti-Na+/K+ -ATPase alpha1, or anti-tubulin antibodies. CFTR band C and band B are indicated by arrows. Tubulin is shown as a loading control. (B) Quantification of the band intensities for (B) experiments expressed as fold change vs. DMSO control. Values in the experiments described are presented as means ± SD (n = 3). Means were tested for statistical significance using a Student’s t-test (*P < 0.05; **P < 0.01). (C) The cell lysates from parental CFBE41o- (P), CFBE/WT-CFTR (WT), and CFBE/F508del-CFTR (F508) cells were analyzed using anti-CFTR antibody 23C5 (our own anti-CFTR antibody) or M3A7 (from Chemicon). The molecular weight (kDa, kilodalton) of the markers was shown on the side of the blot.

et al., 2008a,b). As the binding of nanomolar concentrations of ouabain to Na+/K+ -ATPase α subunits has previously been reported to increase intracellular calcium (Li et al., 2006; Prassas and Diamandis, 2008), we examined the calcium content of the ER stores in WT-CFTR cells and in ouabain treated vs. untreated CFBE/F508del-CFTR cells (see Materials and Methods). As shown...
in Figure 5, the cytosolic calcium concentrations in CFBE/WT-CFTR or in CFBE/F508del-CFTR cells are similar before adding thapsigargin. However, after adding thapsigargin, the ER released Ca$^{2+}$ (ER calcium stores) in CFBE/F508del-CFTR cells were about 32% higher than in CFBE/WT-CFTR cells (**P < 0.008, n = 6), and ouabain treatment reduced ER calcium stores in CFBE/F508del-CFTR cells by ~47% (**P < 0.015, n = 6). Thus, after 24 h of exposure to a low concentration of ouabain, ER calcium stores in CFBE/F508del-CFTR cells were similar to those in CFBE/WT-CFTR cells. And this normalization of ER [Ca$^{2+}$] in F508del-CFTR cells is also observed by low temperature rescue or by other pharmacological corrections (Antigny et al., 2011).

CONNECTIVITY BETWEEN OUABAIN AND LOW TEMPERATURE TRANSCRIPTIONAL PROFILES SUGGESTS A SIMILAR MODE OF ACTION

Genome wide transcriptional profiling can be used to infer similarities between the mechanisms of action of different compounds. The CMAP is a rich compendium of 6100 genome wide transcriptional profiles from cultured human cells that have been treated with 1309 bioactive small molecules, including ouabain, and other cardiac glycosides. Gene signatures that show positive correlation with reference profiles (instances) in the CMAP share functional similarities and provide clues to the mechanisms of action of the compounds (Lamb et al., 2006).

To explore the mechanism of F508del-CFTR correction by ouabain, we used transcriptional profiling of parental CFBE41o-cells subjected to different treatments. We generated gene expression profiles using two levels of stringency that were set using a False Discovery Rate (FDR) of ≤0.01 and ≤0.05 (Benjamini and Hochberg, 1995) and an absolute fold Change (absFC) > 3. The signatures used to query the CMAP (99 probes up- and 208 probes down-regulated) were from polarized parental CFBE41o-cells treated with ouabain for 24 h. As expected we detected ouabain and six other cardiac glycoside reference profiles (instances) in the CMAP with high confidence (Figure 6A, P-value = 0, enrichment score (ES) = 0.995; ES, ranging from +1 means correlated; −1 means anti-correlated). We then queried the CMAP with signatures obtained under three well characterized conditions in which F508del-CFTR trafficking is partially corrected: low temperature rescue (29°C) and the corrector compounds VRT-325 (Loo et al., 2006; Varga et al., 2008) and VX-809 (Van Goor et al., 2011). Remarkably, the low temperature signature (FDR ≤ 0.05; 384 probes up- and 329 probes down-regulated), recovered the ouabain and the other six cardiac glycoside instances with very high ESs (Figure 6B, P-value = 0, and ES = 0.942). At higher stringency (FDR ≤ 0.01; 81 probes up- and 74 probes down-regulated), the low temperature signature remained tightly correlated with the cardiac glycoside instances, including ouabain (Figure 6C, P-value = 0, and ES = 0.972) suggesting that there is a strong similarity. Conversely, when we queried the CMAP with signatures derived from parental CFBE41o-cells treated with VRT-325 and VX-809, which are thought to act as a pharmacological chaperones that directly bind to F508del-CFTR, we found that the 24-h signature for VRT-325 (FDR ≤ 0.05; 20 probes up- and 139 probes down-regulated) was negatively correlated with ouabain instances and VX-809 24 h signature (FDR ≤ 0.05; 97 probes up- and 64 probes down-regulated) null-correlated with ouabain instances (Figure 6D).

We next examined a larger number of probes to explore the broader transcriptional response to ouabain and low temperature (31914 probes/41000 Agilent probes, FDR ≤ 0.05; Figure 7A) and to confirm this relationship by measuring the similarity of
Zhang et al. Rescue of F508del-CFTR by ouabain

FIGURE 4 | Ouabain rescues F508del-CFTR channel activity in in vitro and in vivo assays. (A) CFBE/F508del-CFTR cells treated with ouabain, ouabagenin, digoxin, and digitoxin for 24 h, and iodide efflux was monitored. Data shown are the mean ± SD of n = 4 (*P < 0.03; **P < 0.006). (B) CFBE/F508del-CFTR cells were treated with or without 0.1 µM ouabain for 24 h and CFTR channel activity was measured by Ussing chamber assay. The $\Delta \text{I}_{\text{sc}}$ stimulated by ouabain treatment was compared to low temperature incubation (29˚C, 24 h) and to CFBE/WT-CFTR. Histogram showing the change in $\text{I}_{\text{sc}}$ ($\Delta \text{I}_{\text{sc}}$) after addition of forskolin + genistein, defined as the difference between the sustained phase of the current response after stimulation and the baseline immediately before stimulation. In the bar graph, data are presented as mean ± SEM as compared to DMSO control [(I) n = 9 for CFBE/WT-CFTR cells; (II) n = 6 for 29˚C treatment samples; (III) n = 8 for DMSO control; (IV) n = 7 for ouabain; (V) *P < 0.05; ***P < 0.001]. (C) Salivary secretion in wild-type mice (WT) or F508del-CFTR (F508del) mice treated with vehicle alone or 0.01 mg/kg/day of ouabain for 2 days. Monitored for 30 min following stimulation, results are expressed as the mean ± SEM of n = 5 (*P < 0.04; **P < 0.0004).
with an associated enrichment analysis to identify functional ontologies in MetaCore with ouabain treatment (Figure 8A, right panel). These results suggest that processes associated with the folding and degradation of CFTR were at the interface between the two treatments. To dissect this further we validated a subset of the 3530 common genes by real-time PCR (Figure 8B), selecting the ones that were most differentially expressed by both treatments and associated with the most enriched GO processes. After treatment with ouabain and low temperature we observed a decrease in the expression of chaperone genes such as HSPA8/Hsc70 and HSPA1L/Hsp70 that are involved in protein folding and ER-associated degradation (Figure 8B, respectively 60 and 70% reduced by ouabain, 80 and 60% reduced by low temperature; *P-value < 0.05). To test if this altered level of mRNA could also be detected at the protein level we measured the expression of Hsc70 and Hsp70 protein by immunoblotting (Figure 8C). The expression of Hsc70 and Hsp70 chaperones was decreased and correlated with the appearance of mature F508del-CFTR (glycosylated form, band C), and with increased levels of band B (core-glycosylated form; Figure 8C). In contrast, expression of the Unfolded Protein Response (UPR) marker, HSPA5/Bip decreased with ouabain treatment but remained unchanged at low temperature, while ER chaperones such as calnexin (tested as a control) were unaltered by ouabain or low temperature (Figures 8B,C). We also observed an increase in the SEC24A mRNA and protein expression (Figures 8B,C) following ouabain treatment. Sec24A (COPII complex subunit) implicated in the binding of CFTR destined to traffic from the ER (Routledge et al., 2010) was up-regulated by ouabain treatment but not at low temperature (Figure 8C). At the individual gene level, there were differences in the expression levels between ouabain and low temperature but overall, the striking correlation obtained between the two signatures shows their functional similarities.

**DISCUSSION**

Cardiac glycosides have been in clinical use for centuries to treat heart failure, and the mechanism of their positive inotropic effect is well characterized. Ouabain and other cardiac glycosides bind Na⁺/K⁺-ATPase in cardiac myocytes and act by inhibiting its enzymatic activity or down-regulating its expression (Huang et al., 1997; Hoyer et al., 2011). Cardiac glycosides can induce apoptosis and inhibit the growth of cancer cell lines and the pathway to the clinic is expected to be short because the pharmacodynamics and pharmacokinetics of cardiac glycosides are already well-established (Prassas and Diamandis, 2008). Oleandrin, the most promising first generation glycoside-based anticancer drug, is presently in phase I clinical trials to determine the maximum-tolerated dose and evaluate its effect on the pharmacokinetics on chemotherapies administered concurrently (Yang et al., 2009).

**OUABAIN AND LOW TEMPERATURE TREATMENT GENERATE SIMILAR GENE EXPRESSION PROFILES**

To gain insight into the molecular processes involved in the stability and trafficking of F508del-CFTR we analyzed the common genes following ouabain and low temperature treatments using the GeneGo Cystic Fibrosis platform (MetaCore™ by GeneGo, Inc.). We obtained 3530 genes in common, 8963 unique genes for ouabain and 687 unique genes for low temperature with FDR ≤ 0.05, and the intersection of ouabain and low temperature transcriotnal signatures showed that 84% of the differentially expressed genes at 29°C were also differentially expressed with ouabain treatment (Figure 8A, left panel). We performed enrichment analysis to identify functional ontologies in MetaCore with an associated P-value (Figure 8A, right panel). Enrichment analysis consists of matching gene IDs of possible targets with those in functional ontologies in GeneGo comparison experiments workflow (Shmelkov et al., 2011).

Remarkably, among the common genes shared between ouabain and low temperature treatments we found that the Gene Ontology (GO) processes that were most highly enriched were: Response to Endoplasmic Reticulum Stress (P = 1.11e⁻¹¹), Response to Unfolded Protein (P = 1.13e⁻¹¹), Protein Transport (P = 1.68e⁻¹¹), and the more general Positive Regulation of Biological Processes (P = 1.61e⁻¹¹; Figure 8A, right panel). These results suggest that processes associated with the folding and degradation of CFTR were at the interface between the two treatments. To gain insight into the molecular processes involved in the stability and trafficking of F508del-CFTR we analyzed the common genes following ouabain and low temperature treatments using the GeneGo Cystic Fibrosis platform (MetaCore™ by GeneGo, Inc.). We obtained 3530 genes in common, 8963 unique genes for ouabain and 687 unique genes for low temperature with FDR ≤ 0.05, and the intersection of ouabain and low temperature transcriotnal signatures showed that 84% of the differentially expressed genes at 29°C were also differentially expressed with ouabain treatment (Figure 8A, left panel). We performed enrichment analysis to identify functional ontologies in MetaCore with an associated P-value (Figure 8A, right panel). Enrichment analysis consists of matching gene IDs of possible targets with those in functional ontologies in GeneGo comparison experiments workflow (Shmelkov et al., 2011).

Remarkably, among the common genes shared between ouabain and low temperature treatments we found that the Gene Ontology (GO) processes that were most highly enriched were: Response to Endoplasmic Reticulum Stress (P = 1.11e⁻¹¹), Response to Unfolded Protein (P = 1.13e⁻¹¹), Protein Transport (P = 1.68e⁻¹¹), and the more general Positive Regulation of Biological Processes (P = 1.61e⁻¹¹; Figure 8A, right panel). These results suggest that processes associated with the folding and degradation of CFTR were at the interface between the two treatments. To dissect this further we validated a subset of the 3530 common genes by real-time PCR (Figure 8B), selecting the ones that were most differentially expressed by both treatments and associated with the most enriched GO processes. After treatment with ouabain and low temperature we observed a decrease in the expression of chaperone genes such as HSPA8/Hsc70 and HSPA1L/Hsp70 that are involved in protein folding and ER-associated degradation (Figure 8B, respectively 60 and 70% reduced by ouabain, 80 and 60% reduced by low temperature; *P-value < 0.05). To test if this altered level of mRNA could also be detected at the protein level we measured the expression of Hsc70 and Hsp70 protein by immunoblotting (Figure 8C). The expression of Hsc70 and Hsp70 chaperones was decreased and correlated with the appearance of mature F508del-CFTR (glycosylated form, band C), and with increased levels of band B (core-glycosylated form; Figure 8C). In contrast, expression of the Unfolded Protein Response (UPR) marker, HSPA5/Bip decreased with ouabain treatment but remained unchanged at low temperature, while ER chaperones such as calnexin (tested as a control) were unaltered by ouabain or low temperature (Figures 8B,C). We also observed an increase in the SEC24A mRNA and protein expression (Figures 8B,C) following ouabain treatment. Sec24A (COPII complex subunit) implicated in the binding of CFTR destined to traffic from the ER (Routledge et al., 2010) was up-regulated by ouabain treatment but not at low temperature (Figure 8C). At the individual gene level, there were differences in the expression levels between ouabain and low temperature but overall, the striking correlation obtained between the two signatures shows their functional similarities.

**DISCUSSION**

Cardiac glycosides have been in clinical use for centuries to treat heart failure, and the mechanism of their positive inotropic effect is well characterized. Ouabain and other cardiac glycosides bind Na⁺/K⁺-ATPase in cardiac myocytes and act by inhibiting its enzymatic activity or down-regulating its expression (Huang et al., 1997; Hoyer et al., 2011). Cardiac glycosides can induce apoptosis and inhibit the growth of cancer cell lines and the pathway to the clinic is expected to be short because the pharmacodynamics and pharmacokinetics of cardiac glycosides are already well-established (Prassas and Diamandis, 2008). Oleandrin, the most promising first generation glycoside-based anticancer drug, is presently in phase I clinical trials to determine the maximum-tolerated dose and evaluate its effect on the pharmacokinetics on chemotherapies administered concurrently (Yang et al., 2009).
FIGURE 6 | Ouabain gene expression signature is highly correlated with low temperature. Cartoon depicting the CMAP concept: pattern-matching algorithms score each established profile for the direction (up-or down-regulated) and strength (fold) of enrichment with the query signature (Lamb et al., 2006). CMAP outputs of 100 nM ouabain (or other small molecules) query signatures obtained in polarized parental CFBE41o-cells treated for 24 h at 37˚C and polarized parental CFBE41o-cells treated for 24 h at 29˚C (Low-Temp.). Probes generated a FDR $\leq 0.05$ and an absolute fold change (absFC) $> 3$ were included in the query signatures. Perturbagens are ordered according to their estimated P-values (correlated means = 0) and corresponding connectivity scores, ranging from +1 (correlated) to −1 (anti-correlated). (A) The genomic changes induced in polarized parental CFBE41o-cells by ouabain 24 h query signature is correlated with ouabain and six cardiac glycosides previously established profiles in CMAP (instances). (B) The genomic changes induced in polarized parental CFBE41o-cells by low temperature 24 h specific-signature is highly ranked with ouabain and six cardiac glycoside instances. (C) More stringent query signature (FDR $\leq 0.01$) increases the ability of low temperature to recover ouabain instance in the CMAP. (D) The genomic changes induced in polarized parental CFBE41o-cells by 10 µM VRT-325 and by 1 µM VX-809 query signatures are respectively weakly anti-correlated and null-correlated with the previously established ouabain profile in CMAP.
In contrast to the apoptotic effects of these drugs on cancer cells, low concentrations of ouabain have also been shown to stimulate the proliferation and inhibit cell death in normal cells (Li et al., 2006). It has been reported that digitoxin and other cardiac glycosides at sub-nanomolar concentrations mimic gene therapy with CFTR in vitro and can suppress the hypersecretion of IL-8 by cultured CF airway epithelial cells (Srivastava et al., 2004). More recent data show that digoxin derivates attenuate...
FIGURE 8 | The effects of ouabain and low temperature on ER-related chaperones. (A) Left panel: Venn diagram of the intersection between ouabain and low temperature 24 h signatures according to a FDR ≤ 0.05. The numbers indicate distinct genes. The probability *$P = 0.0001$ was calculated using a hyper-geometric random variable. Right panel: Gene Ontology (GO) cellular processes pie chart of 3530 genes in common between ouabain and low temperature 24 h treatments. (B) The total RNA previously extracted for the microarray analysis was tested by real-time PCR using the individual primers for the gene expressions of HSPA8, HSPA1L, HSPA5, SEC24A, and CANX. Data are presented by the fold change of gene expression vs. DMSO control with mean ± SEM of $n = 3$ (*$P < 0.05$). (C) CFBE/F508del-CFTR cells were treated with 0.1$\mu$M ouabain or 29°C (Low-Temp.) for 6, 24, or 48 h, then the cell lysates were analyzed by immunoblotting using the individual antibodies. The bar graph shows quantification of the band intensities for blots expressed as fold change vs. Time 0 h control. Values in the experiments described are presented as means ± SD ($n = 3$). Means were tested for statistical significance using a Student’s t-test (*$P < 0.05$).
inflammatory lymphocyte function and autoimmune diseases (Huh et al., 2011).

Na⁺/K⁺-ATPase, the target of cardiac glycosides can, in the presence of nanomolar concentrations of ouabain, act as a signal transducer. For instance, it has been reported that ouabain-bound Na⁺/K⁺-ATPase can, independent of its ion transport function, induce multiple signaling pathways including c-Src and intracellular calcium oscillations (Zhang et al., 2006). Several studies have shown that [Ca²⁺] is elevated in CF and becomes normalized when the trafficking of F508del-CFTR is corrected by small molecules or low temperature (Norez et al., 2006, 2009; Antigny et al., 2008a). The relationships between CFTR and calcium signaling have recently been reviewed (Antigny et al., 2011), however the role of [Ca²⁺] in protein biogenesis and trafficking remains incompletely understood. We confirmed the elevation of ER calcium stores in CF cells and showed that ouabain reduces store calcium to normal levels in CFBE cells expressing F508del-CFTR (Figure 5).

Here, we demonstrate that nanomolar ouabain increases F508del-CFTR trafficking to the cell surface and partially restores its function in a human CF bronchial epithelial cell line. Ouabain has this effect without causing substantial inhibition of Na⁺/K⁺-ATPase protein expression or cell viability. Moreover, our in vivo results also showed functional rescue of mutant CFTR by ouabain in CF mice and the value corresponds to ~8.1% of the secretory response of littermate WT control mice and without affecting the mice body weight (control group: starting, 26.36 ± 2.49 g; after 48 h, 26.53 ± 2.63 g, P > 0.2; ouabain treated group: starting, 26.98 ± 2.39 g; after 48 h 27.29 ± 2.33 g, P > 0.2). Thus our data raise the possibility that cardiac glycosides not only increase total CFTR protein expression, but may also increase the folding yield and trafficking of F508del-CFTR. Ouabain thus joins a growing list of F508del-CFTR corrector compounds that act by modulating proteostasis (Calamini et al., 2012) rather than by acting as pharmacological chaperones that bind to F508del-CFTR (Sampson et al., 2011). Considering the inhibition function of cardiac glycosides on inflammation in cultured CF airway epithelial cells (Srivastava et al., 2004), also associating the long history of cardiac glycosides on inflammation in cultured CF airway epithelial cells (Sampson et al., 2011). Considering the inhibition function of cardiac glycosides on inflammation in cultured CF airway epithelial cells (Srivastava et al., 2004), also associating the long history of cardiac glycosides on inflammation and it has been shown that a decrease in expression of Hsc70 (in association with the co-chaperone CHIP) results in decreased degradation of F508del-CFTR (Rab et al., 2007; Matsumura et al., 2011). Moreover, we found an increased expression of SARA (COPII complex subunits; see Supplementary Material) by low temperature incubation. SARA, together with SEC24A, which is up-regulated by ouabain, led to anterograde export of the binding protein to the Golgi (Yoo et al., 2002; Wang et al., 2008). The intersection of ouabain and low temperature transcriptional responses indicates that 84% of the genes that are differentially expressed at 29°C are also differentially expressed with ouabain (Figure 8A, left panel). Thus, ouabain may shift the cells to a "permissive" state by mimicking low temperature, thus correcting the F508del-CFTR folding and trafficking defect.

Dissection of the molecular events that underlie rescue by low temperature and mimicking it with a small molecule may be a strategy to identify CF therapeutics. Galietta and colleagues have shown using CFBE41o-cells that low temperature can synergize with correctors such as corr-4a and VRT-325 (Sondo et al., 2011). Therefore our finding suggests that combination treatments that include ouabain may also be synergistic in the treatment of CF.

In summary, our study shows that low concentrations of ouabain can rescue F508del-CFTR by mimicking low temperature rescue in human CF bronchial epithelial cells. Apart from pharmacological chaperones that bind directly to F508del-CFTR the target of and the mechanism of action of most correctors is unknown. Certainly cardiac glycosides are being investigated for use as a cancer therapeutic and for other diseases (Prassas and Diamandis, 2008). We predict that the Na⁺/K⁺-ATPase or its downstream pathway will be a good place to search for F508del-CFTR correctors.

**MATERIALS AND METHODS**

**CELL CULTURE AND TRANSFECTIONS**

The parental CFBE41o-cell line was originally developed by immortalization of CF (F508del/F508del) bronchial epithelial cells by Dr. D. Gruenert (Kunzelmann et al., 1993). The mutated
Zhang et al. Rescue of F508del-CFTR by ouabain

Frontiers in Pharmacology | Pharmacology of Ion Channels and Channelopathies October 2012 | Volume 3 | Article 178 | 12

protein is expressed at low levels in this cell line, therefore two derivatives were generated by transduction using the TranzVector lentivirus system (Wu et al., 2000) to create CFBE/WT-CFTR and CFBE/F508del-CFTR cell lines in which the CFTR protein can be detected by immunoblotting. Those cells were generously provided by Dr. J. P. Clancy (University of Alabama, Birmingham) and cultured in EEMEM medium supplemented with 10% FBS. Polarized CFBE41o-cells were cultured initially under liquid–liquid conditions, then allowed to polarize at the air–liquid interface. BHK cells stably expressing F508del-CFTR-3HA were cultured as described previously (Carlile et al., 2007).

THE CELL-BASED TRAFFICKING ASSAY

The surface expression of CFTR was measured as described previously (Carlile et al., 2007). BHK cells stably expressing F508del-CFTR-3HA (bearing a 3HA-epitope tag in the fourth extracellular loop) were treated with cardiac glycosides. Cells were fixed with 4% paraformaldehyde for 15–20 min at 4°C and incubated with monoclonal anti-HA antibody (Sigma, Canada) solution containing 1% FBS at 4°C overnight. After washing, the plates were analyzed using a plate reader (Analysetm HT 96.384, Biosystems, USA; 488 nm excitation, 510 nm emission) to measure background fluorescence, then incubated with anti-mouse IgG antibody conjugated with FITC (Sigma, Canada) at a dilution of 1:100 for 1 h. The cells were washed, then incubated with 100 µl of PBS, and reanalyzed. The mean fluorescence of 12 mock (DMSO) treated wells was used as the background signal and designated 0% cell surface signal. The surface CFTR signal of cells expressing WT-CFTR on the same plate was designated 100%. The compound treated cell fluorescent signal was then given a percentage value relative to these two controls. Control experiments indicated that the vehicle did not affect trafficking when added alone (data not shown).

IMMUNOBLOTTING AND ANTIBODIES

Cells were lysed in RIPA buffer containing 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 20 mM Tris-HCl (pH 8.0), and 0.08% deoxycholic acid, and lysates were separated by 6% SDS-PAGE and transferred to nitrocellulose filters. The filters were probed with monoclonal anti-tubulin (Sigma), anti-CFTR (monoclonal antibody 23CS, P. Määttänen, M. Mirza, and D. Y. Thomas, unpublished results), anti-CFTR (M3A7, Chemicon), anti-BiP (BD Transduction Laboratories), anti-Hsp70 (Stressgen), rabbit polyclonal anti-calnexin (kindly provided by Dr. J. J. Bergeron, McGill University), rabbit anti-Sec24A (Novus Biologicals), and rabbit anti-Hsc70 antibodies (StressMarq). Horseradish peroxidase (HRP)-conjugated secondary antibodies were used and blots were developed using the ECL detection system (Roche, Germany) and exposed to film (Amersham). The films were scanned and analyzed by densitometry using Photoshop (Adobe, Inc.). Quantification of the band intensities for Figures 2B and 8C experiments expressed as fold change vs. DMSO control and normalized by tubulin bands.

CYTOTOXICITY ASSAY

The cytotoxic effects of ouabain or other cardiac glycosides (from Sigma) were determined by using the colorimetric AlamarBlue™ (Biosource, Camarillo, CA, USA) assay, according to the manufacturer’s instructions. Briefly, cells were plated in triplicate at a density of 3 × 10^4 cells/per well in 96-well plates and cultured overnight. Cells were then treated with the different concentrations of ouabain or other cardiac glycosides for 24 h. The medium was removed after 24 h and cells were incubated in fresh medium at 37°C, 5% CO_2 for 4 h. At the end of the 4-h incubation, 10 µl of AlamarBlue was added to each well and incubated at 37°C, 5% CO_2 for 18 h. Absorbance was measured at 570 and 600 nm and medium without cells was used as blank. Percent survival was quantified according to the manufacturer’s instructions and the untreated sample was set to 100%. Final percent survival was averaged from three triplicates from three independent experiments.

STATISTICS

Values in the experiments described are presented as means ± SD. Means were tested for statistical significance using the Student’s t-test.

IODIDE EFFLUX ASSAYS

Cystic fibrosis transmembrane conductance regulator channel activity was assayed by measuring iodide efflux with a robotic liquid handling system (BioRobot 8000, Qiagen, USA) using Qia-gen 4.1 Software as described previously (Robert et al., 2008). Cells were seeded in 24-well plates allowed to reach 100% confluence, and treated with drug or vehicle for an additional 24 h. Cells were then incubated in iodide loading buffer [136 mM NaI, 3 mM KNO_3, 2 mM Ca(NO_3)_2, 11 mM glucose, and 20 mM Hepes pH 7.4] for 1 h at 37°C, then washed with efflux buffer [136 mM NaNO_3, 3 mM KNO_3, 2 mM Ca(NO_3)_2, 11 mM glucose, and 20 mM Hepes, pH 7.4] and the appearance of I^- was measured after replacing the buffer at 1 min intervals before and during stimulation with 50 µM genistein and 10 µM forskolin using an iodide-sensitive electrode (Orion Research, Inc., Boston, MA, USA). Relative iodide efflux rates were calculated from the difference between the maximal (peak) iodide concentration during stimulation and the minimal iodide concentration before stimulation.

USING CHAMBER STUDIES

Cystic fibrosis transmembrane conductance regulator channel activity was measured in Using chambers as described previously (Robert et al., 2010). Briefly, 2 × 10^6 cells (CFBE/WT-CFTR or CFBE/F508del-CFTR cells) were seeded onto fibronectin-coated Snapwell 12-mm inserts (Corning Incorporated, Life Sciences, NY, USA) and the apical medium was removed the following day to create an air–liquid interface. Trans-epithelial resistance was monitored using an EVM epithelial volt ohm meter (World Precision Instruments, Sarasota, FL, USA) and cells were used when the trans-epithelial resistance of the monolayer was 300–400 Ω cm². In some experiments, CFBE/F508del-CFTR monolayers were grown at 29°C or treated with a test compound at 37°C for 24 h before being mounted in chambers and voltage-clamped using a VCCMC multichannel current-voltage clamp (Physiologic Instruments, San Diego, CA, USA). Apical membrane conductance was functionally isolated by permeabilizing the basolateral membrane with 200 µg/ml nystatin and imposing an apical-to-basolateral Cl^- gradient. The apical bathing solution contained
115 mM NaCl, 25 mM NaHCO₃, 1.2 mM MgCl₂, 1.2 mM CaCl₂, 2.4 mM KH₂PO₄, 1.24 mM K₂HPO₄, 10 mM mannitol (pH 7.4 with NaOH). The basolateral bathing solution contained 1.2 mM NaCl, 115 mM Na-glucronate, 25 mM NaHCO₃, 1.2 mM MgCl₂, 4 mM CaCl₂, 2.4 mM KH₂PO₄, 1.24 mM K₂HPO₄, 10 mM glucose (pH 7.4 with NaOH). CaCl₂ was increased to 4 mM to compensate for its chelation by glucronate. The apical solution contained mannitol instead of glucose to eliminate current mediated by Na⁺-glucose cotransporters. Successful permeabilization of the basolateral membrane under these conditions was obvious from the reversal of I_sc. Solutions were continuously gassed and stirred with 95% O₂-5% CO₂ and maintained at 37°C. Ag/AgCl reference electrodes were used to measure trans-epithelial voltage and pass current. Pulses (1 mV amplitude, 1 s duration) were imposed every 90 s to monitor resistance. The voltage clamps were connected to a PowerLab/SP interface (ADInstruments, Colorado Springs, CO, USA) for data collection. Ten micromolar forskolin +50 μM genistein were added to the apical bathing solution to activate CFTR.

**SALIVARY SECRETION**

The salivary secretion assay was performed as described (Best and Quinton, 2005). Briefly, homozygous ΔF508-CFTR mice (C57BL6J/Eur) and WT mice were 10–12 weeks old and when used weighed 20–25 g. A micro pump (Alzet Model 1003D) was fixed under the skin on the back of mouse to deliver a very low dose of ouabain (0.01 mg/kg/day) or vehicle for 48 h. Mice were anesthetized using ketamine and diazepam and 1 mM atropine was injected subcutaneously into the left cheek to block cholinergic responses. After absorbing any saliva with Whatman filter paper, 100 μM isoproterenol was injected at the same site with 1 mM atropine to induce secretion and saliva was collected on filter paper every 3 min for 30 min. Samples were immediately sealed in a pre-weighed vial and the saliva secretion rate and the total amount were normalized to mouse weight. All procedures were performed according to guidelines developed by the Canadian Council on Animal Care and the protocol was approved by the McGill University Animal Care Committee.

**ER CALCIUM STORE MEASUREMENTS**

Thapsigargin-releaseable ER calcium was calculated as the difference in cytoplasmic calcium measured before and after the addition of 2 μM thapsigargin to cells in Ca²⁺-free buffer. In brief, the cells were grown and treated with or without 0.1 μM ouabain for 24 h, then 2 × 10⁶ cells (CFBE/WT-CFTR or CFBE/F508del-CFTR cells) were harvested and washed in Ca²⁺-free buffer (20 mM HEPES, pH 7.4, 143 mM NaCl, 6 mM KCl, 1 mM MgSO₄, 0.1% glucose, 0.1% bovine serum albumin, 250 mM sodium pyruvate). The cells were resuspended in 200 μl of calcium-free buffer containing 0.02% pluronic acid and subsequently loaded with the cell-permeable fluorescent indicator Fura-2/AM at 3 mM for 30 min at 37°C. After a final wash, the cells were resuspended in Ca²⁺-free buffer and a 340/380-nm excitation ratio at a 510-nm emission wavelength were obtained using a LS 50B PerkinElmer Life Sciences luminescence spectrophotometer. The fluorescence ratio (340/380) was measured in cells treated with 2 μM thapsigargin and the Fura-2 ratio values converted to [Ca²⁺] by according to Grynkiewicz et al. (1985). The peak of thapsigargin-releaseable [Ca²⁺] was calculated as the difference in cytoplasmic calcium measured before and after the addition of 2 μM thapsigargin to cells in Ca²⁺-free Hanks' buffer.

**MICROARRAY ANALYSIS**

Polarized parental CFBE41o-cells cultured at the air–liquid interface were used for microarray assays. RNA samples were extracted in 1 ml TRIzol Reagent (Invitrogen, USA), quantified by spectrophotometry (Nanodrop, USA), and RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only samples with an RNA integrity number (RIN) ≥ of 8 were used for amplification. Total RNA (1 mg) was subjected to two rounds of amplification using the Amino Allyl MessageAMP II aRNA amplification kit (Ambion, Applied Biosystems, USA). The integrity and quantity of the aRNA was reevaluated by Nanodrop and Agilent Bioanalyzer, and coupled to Cy3 and Cy5 (Amersham Biosciences, UK). Whole Human Genome 44 K arrays (Agilent Technologies, product G4112A) were used for all experiments. RNA samples (825 ng/each) were subjected to fragmentation following by 16 h hybridization, washing, and scanning (Agilent Technologies, model G2505B) according to the manufacturer’s protocol (manual ID #G4140-90030). Samples were hybridized against Universal Human Reference RNA (Stratagene, ID #740000, La Jolla, CA, USA). Duplicate hybridizations were performed for each sample using reverse-dye labeling. Arrays were washed according to manufacturer’s recommendations, scanned using an Agilent dual-laser microarray scanner (Model G2505B), and Cy5/Cy3-signals were quantified using Agilent’s Feature Extraction software (v.7.11) with the default parameters.

Microarray quality control reports generated by the Agilent Feature Extraction software were used to detect hybridization artifacts. Probe level raw intensities were processed using R/BioConductor and Limma package (Gentleman et al., 2004). Data were background corrected using “normexp” limma method and normalized in two steps: loess normalization within-array to correct systematic dye-bias and quantile normalization between-arrays to detect systematic non-biological bias. Ratios representing the relative target mRNA intensities compared to Universal Human Reference RNA probe signals were derived from normalized data. To remove “batch effects” across microarray experiments we adjusted the data using the empirical Bayes method available at: http://biosun1.harvard.edu/complab/batch/ (Johnson et al., 2007). PCA plots and Clustering trees of normalized adjusted intensities were drawn for each time-point specific sets of samples to confirm the robustness of the method used.

To find differentially expressed genes (treatment vs. control), a t-test was applied for each time-point. For each P-value, the Benjamini–Hochberg procedure was used to calculate the FDR (Benjamini and Hochberg, 1995). Genes were considered to be differentially expressed if the corrected FDR ≤ 0.05 (while controlling the expected FDR to no more than 5%). Unsupervised hierarchical clustering was performed on normalized data (FDR < 0.05), with complete linkage and Euclidian and Pearson’s correlation distances.
FUNCTIONAL CATEGORY ENRICHMENT ANALYSES

Identification of overrepresented functional categories (pathways and cellular processes) was performed per treatments using the complete set of differentially expressed genes (FDR ≤ 0.05) in the MetaCore™ suit (Version 6.1; GeneGo, Inc., St. Joseph, MI, USA; Nikolsky et al., 2005). The functional analysis were based on MetaCore’s proprietary manually curated data base of CF specific contents (Nikolsky et al., 2009).

REAL-TIME PCR

Total RNA was extracted from cells using TRIzol Reagent (Life Technologies, Inc., Burlington, ON, Canada), and the cDNA was synthesized using AffinityScript QPCR cDNA Synthesis Kit (Stratagene, La Jolla, CA, USA) as follows: 20 µl reaction solution contained 10 µl SYBR Green Supermix (Bio-Rad Laboratories, Inc., Hercules, CA, USA); 0.4 µl sense and reverse primer (25 ng/µl); 2 µl diluted cDNA; 7.2 µl nuclease-free water. For the cross-validation real-time PCR experiments we used the same total RNA extracted for the microarray assays. The primer sequences were designed according to the GenBank™ accession numbers: GAPDH NM_002046; CFTR NM_000492; HSPA8 NM_000527; HSPA1L NM_000324; SEC24A NM_021982; and CANX NM_01746. The subsequent data analysis was performed using MxPro™ QPCR Software followed by comparative quantification real-time PCR. Gene expression levels were normalized to GAPDH gene expression and compared with untreated control, which was assigned a value of 1.

ACKNOWLEDGMENTS

We acknowledge infrastructure support and technical assistance from the Breast Cancer Functional Genomics Group – McGill University, which is supported by funds from the CIHR. Suzana M. Anjos was supported by fellowships from the Canadian Cystic Fibrosis Foundation. Fabiana Ciciriello, was supported by postdoctoral fellowship from Pasteur Institute-Fondazione Cenci Bolognetti, and by prof. Di Mauro E. research fellowship at the Biology and Biotechnology Charles Darwin, BBCD department, Sapienza University, Rome, Italy. We would like to thank di Bernardo D. for providing bioinformatics support. This work was funded by the Canadian Institutes of Health Research CIHR grants CGP-95270, IR0-97568 (John W. Hanrahan and David Y. Thomas).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://www.frontiersin.org/Pharmacology_of_Ion_Channels_and_Channelopathies/10.3389/fphar.2012.00176/abstract

REFERENCES

Anderson, M. P., Berger, H. A., Rich, D. P., Gregory, R. J., Smith, A. E., and Welsh, M. J. (1991). Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 67, 775–784. Antigny, F., Norez, C., Becq, F., and Vandebrouck, C. (2008a). Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. Cell Calcium 43, 175–183. Antigny, F., Norez, C., Cantereau, A., Becq, F., and Vandebrouck, C. (2008b). Abnormal spatial diffusion of Ca2+ in F508del-CFTR airway epithelial cells. Respir. Res. 9, 70. Antigny, F., Norez, C., Becq, F., and Vandebrouck, C. (2011). CFTR and Ca signaling in cystic fibrosis. Front. Pharmacol. 2:67. doi: 10.3389/fphar.2011.00067 Aperia, A. (2007). New roles for an old enzyme: Na,K-ATPase emerges as an interesting drug target. J. Intern. Med. 261, 44–52. Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate – a practical and powerful method to multiple testing. J. R. Stat. Soc. B Stat. Methodol. 57, 289–300. Best, J. A., and Quinton, P. M. (2005). Salivary secretion assay for drug efficiency for cystic fibrosis in mice. Exp. Physiol. 90, 189–193. Caci, E., Caputo, A., Hinzpeter, A., Aroux, N., Fanen, P., Sonawane, N., et al. (2008). Evidence for direct CFTR inhibition by CFTRinh-172 based on Arg347 mutagenesis. Biochem. J. 413, 135–142. Calamini, B., Silva, C. M., Madoux, F., Hurt, D. M., Khanna, S., Chalifant, M. A., et al. (2012). Small-molecule proteostasis regulators for protein conformational diseases. Nat. Chem. Biol. 8, 185–196. Carlile, G. W., Robert, R., Zhang, D., Teske, K. A., Luo, Y., Hanrahan, J. W., et al. (2007). Correctors of protein trafficking defects identified by a novel high-throughput screening assay. ChemBiochem 8, 1012–1020. Cheng, S. H., Gregory, R. I., Marshall, J., Paul, S., Souza, D. W., White, G. A., et al. (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827–834. Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Dott, K., Dreyer, D., et al. (1991). Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354, 526–528. Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., and Welsh, M. J. (1992). Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761–764. Dormer, R. L., Harris, C. M., Clark, Z., Pereira, M. M., Douli, I. J., Norez, C., et al. (2005). Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 60, 55–59. Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. (1998). Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95, 14863–14868. French, P. J., van Doorninck, J. H., Peters, R. H., Verbeek, E., Ameen, N. A., Marino, C. R., et al. (1996). A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. J. Clin. Invest. 98, 1304–1312. Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Duotso, S., et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80. Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985). A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440–3450. Hoyer, K., Song, Y., Wang, D., Phan, B., Dalschi, J., Ingwall, J. S., et al. (2011). Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat. Chem. Biol. 6, 25–33. Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., and Riordan, J. R. (1995). Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83, 129–135. Johnson, W. E., Li, C., and Rabinovic, A. (2007). Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatist ics 8, 118–127. Jurkewnaita, A., Chen, L., Bartoszewski, R., Goldstein, R., Bebok, Z., Mat alon, S., et al. (2010). Functional stability of rescued delta F508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 42, 363–372.
Kartner, N., Hanrahan, J. W., Jensen, T. J., Naismith, A. L., Sun, S. Z., Ackerley, C. A., et al. (1991). Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance. Cell 64, 681–691.

Kunzelmann, K., Schwiebert, E. M., Zschocke, J., Nikolai, W., Kuntzen, B. A., and Grunert, D. C. (1993). An immortalized cystic fibrosis tracheal epithelial cell line homologous for the delta F508 CFTR mutation. Am. J. Respir. Cell Mol. Biol. 8, 522–529.

Lamb, J., Crawford, E. D., Peck, D., Modell, I. W., Blat, I. L., Wrobel, M. J., et al. (2006). The ConnectMap: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935.

Loo, T. W., Bartlett, M. C., Wang, Y., Li, J., Zelenin, S., Aperia, A., and Aizman, Norez, C., Antigny, F., Noel, S., Vandenbroucke, C., and Becq, F. (2009). A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis disease phenotype. Am. J. Respir. Cell Mol. Biol. 41, 217–225.

Pedemonte, N., Lukacs, G. L., Du, K., Caci, E., Zegarra-Moran, O., Galietta, L. J., et al. (2005). Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J. Clin. Invest. 115, 2564–2571.

Pilewski, J. M., and Frizzell, R. A. (1999). Role of CFTR in airway disease. Physiol. Rev. 79, S215–S255.

Prassas, I., and Diamandis, E. P. (2008). Novel therapeutic applications of cardiac glycodies. Nat. Rev. Drug Discov. 7, 926–935.

Rah, A., Bartoszewski, R., Jurkuvnenaitė, A., Wakefield, J., Collawn, J. F., and Bebok, Z. (2007). Endoplasmic reticulum stress and the unfolded protein response: regulatory networks in the unfolded protein response. Cell 127, 1353–1364.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of a cDNA. Science 245, 1066–1073.

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characteri...